Medical device companies developing clinically useful products often benefit from the support of key opinion leaders (KOL) and champions of their technology. Sometimes, however, clinical study sites are selected solely on this basis, leaving other equally important factors inadequately evaluated.
This paper examines the factors that any company planning a clinical study should consider before signing a clinical site agreement.
Author: Donawa Lifescience Consulting Srl
What is in the report
Copyright © 2016 UBM